Clinical potential of elacytarabine in patients with acute myeloid leukemia.

about

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

P2860

Q50923400-AF5D1F73-EF0D-4896-B40A-FB3CC3C96262

P2860

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q38282095

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

@en

type

Item

label

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

@en

prefLabel

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

@en

P1476

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

@en

P2093

David A Rizzieri

http://www.w3.org/2001/XMLSchema#string

Lindsay A M Rein

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity

Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study.

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs.

Potential mechanisms of resistance to cytarabine in AML patients.

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia

1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview.

P304

211-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620714552615

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25469211

http://www.w3.org/2001/XMLSchema#string

P932

4250268

http://www.w3.org/2001/XMLSchema#string

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

about

P2860

P2860

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932